Starting July 1, 2026, Medicare covers GLP-1 medications for weight loss for the first time. The program is called the Medicare GLP-1 Bridge, it charges a flat $50 a month, and it covers Wegovy, Zepbound, and the newly approved Foundayo tablet. For a population that has been almost entirely excluded from these medications on cost grounds, this is the single biggest access change since the drugs launched.
The essentials
- ✓Starts July 1, 2026 — a CMS demonstration program, not a permanent benefit change
- ✓Flat $50 monthly copay, regardless of which covered drug or dose you are on
- ✓Covers Wegovy, Zepbound, and Foundayo (the orforglipron tablet approved in April 2026)
- ✓For Medicare Part D enrollees — the drugs are furnished outside the normal Part D benefit structure
Why this is a bigger deal than it sounds
Medicare has historically been prohibited from covering drugs used for weight loss. That exclusion dates to the Medicare Modernization Act and it produced an absurd situation: the population with the highest prevalence of obesity-related disease had the least access to the most effective treatment for it.
Workarounds existed but were narrow. A Medicare beneficiary could get semaglutide covered as Ozempic if they had type 2 diabetes, or Wegovy if they had established cardiovascular disease and the prescription was written for risk reduction rather than weight. Everyone else paid cash — which, at list prices above $1,000 a month, meant almost nobody.
The Bridge program changes that for the first time. A flat $50 a month is affordable on a fixed income in a way that $1,000 never was.
What's covered
| Medication | Type | Your cost |
|---|---|---|
| Wegovy | Weekly semaglutide injection | $50/month |
| Zepbound | Weekly tirzepatide injection | $50/month |
| Foundayo | Daily orforglipron tablet | $50/month |
The flat copay is the notable design choice. Zepbound at 15 mg costs the same $50 as Zepbound at 2.5 mg, which removes the financial pressure to under-titrate that affects almost every cash-pay patient.
A demonstration, not a permanent benefit
The Bridge sits inside a broader CMS effort — the BALANCE model — covering GLP-1s for obesity across Medicare and Medicaid. It is structured as a demonstration program with a defined scope, which means two things worth planning around.
First, eligibility criteria apply and not every Part D enrollee will qualify. Check your specific situation rather than assuming.
Second, demonstrations are evaluated and can be extended, modified, or allowed to lapse. If you start treatment under the Bridge, have a conversation with your clinician early about what happens to your access if the program changes — and about whether a taper plan makes sense rather than an abrupt stop.
Where to enrol
The drugs under the Bridge are furnished outside the normal Part D structure, so the route in is not identical to filling an ordinary prescription. Several channels participate, including Amazon Pharmacy, which publishes its own Bridge program details.
Start with Medicare's own materials and your Part D plan, then ask your prescriber which participating channel they can route to. Confirm the $50 figure applies to your specific drug and situation before you rely on it.
What older adults should discuss with a clinician first
Affordable access is not the same as clinical suitability. GLP-1 therapy in older adults carries considerations that matter less at 40 than at 70.
Lean mass loss is the main one. A quarter to a third of GLP-1 weight loss is typically lean tissue, and sarcopenia — age-related muscle loss — is already a concern in this population. Losing muscle you were already short of raises fall risk and undermines functional independence. Adequate protein intake and resistance training are not optional additions here; they are part of the treatment.
Dehydration and interactions with existing medications also deserve more attention in an older patient on several prescriptions. None of this argues against treatment. It argues for treatment with a clinician who is watching for it.
Bottom line
If you are on Medicare and have wanted a GLP-1 but couldn't justify the cost, check your eligibility for the Bridge program. A flat $50 a month for Wegovy, Zepbound, or Foundayo is a fundamentally different proposition from what was available before July 2026.
See our guide to GLP-1 medications for older adults for the clinical considerations that come with it.